These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24777680)

  • 1. Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.
    Yan J; Pankhong P; Shin TH; Obeng-Adjei N; Morrow MP; Walters JN; Khan AS; Sardesai NY; Weiner DB
    Cancer Immunol Res; 2013 Sep; 1(3):179-189. PubMed ID: 24777680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
    Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
    Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice.
    Rusakiewicz S; Dosset M; Mollier K; Souque P; Charneau P; Wain-Hobson S; Langlade-Demoyen P; Adotévi O
    Vaccine; 2010 Aug; 28(38):6374-81. PubMed ID: 20654669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of expression vector of hTERT- hIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT.
    Tong XM; Zheng SE; Bader A; Yao HP; Wu NP; Altmeyer P; Brockmeyer NH; Jin J
    Eur J Med Res; 2008 Jan; 13(1):7-14. PubMed ID: 18226991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo.
    Adotévi O; Mollier K; Neuveut C; Dosset M; Ravel P; Fridman WH; Tartour E; Charneau P; Wain-Hobson S; Langlade-Demoyen P
    Blood; 2010 Apr; 115(15):3025-32. PubMed ID: 20130242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT).
    Liao ZL; Tang XD; Lü MH; Wu YY; Cao YL; Fang DC; Yang SM; Guo H
    Cancer Sci; 2012 Nov; 103(11):1920-8. PubMed ID: 22909416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.
    Walters JN; Ferraro B; Duperret EK; Kraynyak KA; Chu J; Saint-Fleur A; Yan J; Levitsky H; Khan AS; Sardesai NY; Weiner DB
    Mol Ther; 2017 Apr; 25(4):976-988. PubMed ID: 28237837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice.
    Pliquet E; Ruffie C; Escande M; Thalmensi J; Najburg V; Combredet C; Bestetti T; Julithe M; Liard C; Huet T; Wain-Hobson S; Tangy F; Langlade-Demoyen P
    Cancer Immunol Immunother; 2019 Apr; 68(4):533-544. PubMed ID: 30656384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product.
    Su Z; Vieweg J; Weizer AZ; Dahm P; Yancey D; Turaga V; Higgins J; Boczkowski D; Gilboa E; Dannull J
    Cancer Res; 2002 Sep; 62(17):5041-8. PubMed ID: 12208759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diepitope multiple antigen peptide of hTERT trigger stronger anti-tumor immune responses in vitro.
    Liao ZL; Luo G; Xie X; Tang XD; Bai JY; Guo H; Yang SM
    Int Immunopharmacol; 2013 Aug; 16(4):444-50. PubMed ID: 23714071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.
    Mennuni C; Ugel S; Mori F; Cipriani B; Iezzi M; Pannellini T; Lazzaro D; Ciliberto G; La Monica N; Zanovello P; Bronte V; Scarselli E
    Cancer Res; 2008 Dec; 68(23):9865-74. PubMed ID: 19047167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
    Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
    Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.
    Aloysius MM; Mc Kechnie AJ; Robins RA; Verma C; Eremin JM; Farzaneh F; Habib NA; Bhalla J; Hardwick NR; Satthaporn S; Sreenivasan T; El-Sheemy M; Eremin O
    J Transl Med; 2009 Mar; 7():18. PubMed ID: 19298672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
    Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
    J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of anti-tumour immunity by dendritic cells transduced with hTERT recombinant adenovirus in mice.
    Chen L; Tang XD; Yu ST; Ai ZH; Fang DC; Cai YG; Luo YH; Liang GP; Yang SM
    J Pathol; 2009 Apr; 217(5):685-92. PubMed ID: 19142972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.
    Dosset M; Godet Y; Vauchy C; Beziaud L; Lone YC; Sedlik C; Liard C; Levionnois E; Clerc B; Sandoval F; Daguindau E; Wain-Hobson S; Tartour E; Langlade-Demoyen P; Borg C; Adotévi O
    Clin Cancer Res; 2012 Nov; 18(22):6284-95. PubMed ID: 23032748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
    Parkhurst MR; Riley JP; Igarashi T; Li Y; Robbins PF; Rosenberg SA
    Clin Cancer Res; 2004 Jul; 10(14):4688-98. PubMed ID: 15269141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects and challenges of building a cancer vaccine targeting telomerase.
    Vonderheide RH
    Biochimie; 2008 Jan; 90(1):173-80. PubMed ID: 17716803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.